FDA panel recommends approval of Chelsea's Northera treatment
from The Wall Street Journal
A U.S. Food and Drug Administration advisory panel has recommended the approval of Chelsea Therapeutics International Ltd.'s drug Northera for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure, such as Parkinson's disease. Shares surged 69 percent to $4.08 in recent after-hours trading as Chelsea said the FDA's cardiovascular and renal drugs advisory committee voted 7 to 4, with one abstention and one non-vote, to recommend Northera's approval.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063